AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6334320
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate sachet (1 X 500 mg)
Trial: 31745048
Drug: Mini-implant anchorage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implant anchorage system
Trial: 30470323
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (Pain Course)
Trial: 27631178
Drug: Calcitriol supplementation
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol supplementation (25 µg) plus hypocaloric diet
Trial: 21950736
Drug: Caffeine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2 × 200 mg)
Trial: 21950736
Drug: Modafinil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (2 × 100 mg)
Trial: 17614214
Drug: Intervention materials
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention materials for smokers in contemplation, preparation, action, and maintenance
Trial: 9792578
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment (continuous positive airway pressure)
Trial: 65221
Drug: MOPP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP and ABDV chemotherapy with local radiotherapy
Trial: 30352537
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral morphine administration
Trial: 23333117
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (carboplatin and paclitaxel)
Trial: 23333117
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with standard chemotherapy
Trial: 17512159
Drug: Assessment period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment period before treatment entry
Trial: 17512159
Drug: Treatment entry
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment entry period
Trial: 11713727
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment on the control side
Trial: 8004613
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for younger or premenopausal women
Trial: 8004613
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen for older or postmenopausal women with estrogen receptor-positive tumors
Trial: 8004613
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (general)
Trial: 3555968
Drug: bufexamac (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bufexamac (20 mg)
Trial: 3555968
Drug: methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone (40 mg)
Trial: 21110088
Drug: Low MeHg
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low MeHg (0.76 mg kg⁻¹)
Trial: 21110088
Drug: Medium MeHg
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium MeHg (7.88 mg kg⁻¹)
Trial: 21110088
Drug: High MeHg
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High MeHg (16.22 mg kg⁻¹)
Trial: 21110088
Drug: Control (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.04 mg kg⁻¹)
Trial: 12660669
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (500-1000 mg) plus hypertonic saline solution (HSS) infusion (150 mL of 1.4%-4.6% NaCl) twice a day for 6 to 12 days.
Trial: 12660669
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (500-1000 mg) as bolus twice a day for 6 to 12 days without HSS.
Trial: 9365428
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL syrup of ipecac administered at 5 minutes after ingestion of 3900 mg acetaminophen
Trial: 9365428
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL syrup of ipecac administered at 30 minutes after ingestion of 3900 mg acetaminophen
Trial: 9365428
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL syrup of ipecac administered at 60 minutes after ingestion of 3900 mg acetaminophen
Trial: 9365428
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ipecac administration)
Trial: 8261835
Drug: famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg twice a day
Trial: 8261835
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg twice a day
Trial: 3493854
Drug: Trivalent live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live, oral polio vaccine (Sabin)
Trial: 3493854
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received initial dose at 2 months of age)
Trial: 31216297
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment
Trial: 29609704
Drug: Non-CPAP (best
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-CPAP (best medical treatment)
Trial: 25344393
Drug: TEAMS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEAMS therapy plus treatment‐as‐usual (TAU)
Trial: 18283036
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m(2) (P500)
Trial: 18283036
Drug: Pemetrexed 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 900 mg/m(2) (P900)
Trial: 11824857
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg (increased to 10 mg if needed)
Trial: 11824857
Drug: Chlorthalidone 15
RxNorm normalized name: chlorthalidone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 15 mg (increased to 30 mg if needed)
Trial: 31827356
Drug: Inhaled 1600
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 1600 μg Salbutamol (SAL)
Trial: 23866771
Drug: Usual DVA
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual DVA agency support plus psychological intervention (SPA sessions weekly or fortnightly, with two follow-up sessions at 1 month and 3 months)
Trial: 19946937
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (aripiprazole and risperidone)
Trial: 17562526
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Diazepam (DZP) in older subjects
Trial: 17562526
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Diazepam (DZP) in young subjects
Trial: 17562526
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Diazepam (DZP) in young subjects
Trial: 11848262
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg perindopril
Trial: 2175584
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg perindopril
Trial: 2864420
Drug: Oral phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phenytoin formulations (5 different formulations, 300 mg each)
Trial: 2864420
Drug: Intravenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phenytoin (300 mg)
Trial: 27029681
Drug: Deferiprone alone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone alone (75 mg/kg/day in 3 divided doses)
Trial: 27029681
Drug: Deferasirox alone
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox alone (30 mg/kg/day single dose)
Trial: 27029681
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (same doses as monotherapy)
Trial: 27029681
Drug: Deferiprone and
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone and Deferasirox (monotherapy and combination)
Trial: 23257371
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (>200 mg daily)
Trial: 23257371
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (≤200 mg daily)
Trial: 20132540
Drug: Intensive smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive smoking cessation intervention (brief motivational interview, intensive motivational interview with pharmacotherapy, reinforcing intervention)
Trial: 15966884
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix proteins (EMPs, Emdogain Gel)
Trial: 15966884
Drug: Tetracycline-coated e-PTFE
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline-coated e-PTFE membrane (MEMP) adjunct to EMP
Trial: 12839637
Drug: Millimeter wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Millimeter wave irradiation and routine medication
Trial: 12839637
Drug: Pretending millimeter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretending millimeter wave irradiation and routine medication
Trial: 10341371
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of prednisone (n = 12)
Trial: 8607399
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins (A: 50,000 IU/day, C: 1,000 mg/day, E: 400 mg/day, beta-carotene: 25 mg/day)
Trial: 2013589
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression and aspirin
Trial: 2013589
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression and low-dose warfarin
Trial: 27287084
Drug: LNG/EE extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE extended regimen (84 days of LNG 150 µg/EE 30 µg with 7 days of EE 10 µg)
Trial: 27287084
Drug: LNG/EE 21/7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE 21/7 (21 days of LNG 100 µg/EE 20 µg with 7 days of placebo)
Trial: 24901757
Drug: Robotic knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic knee brace therapy
Trial: 18818160
Drug: Purple sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple sweet potato leaves (PSPL) 200 g/d containing 902 mg polyphenols
Trial: 16328673
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (L-B) for local infiltration and intraperitoneal instillation
Trial: 16328673
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) for local infiltration and Levobupivacaine 0.25% (L-B) for intraperitoneal instillation
Trial: 16328673
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (L-B) for intraperitoneal instillation and Normal saline (NS) for local infiltration
Trial: 16328673
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (L-B) for both local infiltration and intraperitoneal instillation
Trial: 14585107
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (traditional dietary treatment)
Trial: 8744662
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 15 mL saline (M)
Trial: 8744662
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 15 mL 0.5% bupivacaine (MIB)
Trial: 8744662
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 15 mL 0.5% bupivacaine at the L3‐L4 level (MEB)
Trial: 31671757
Drug: Iron (5
RxNorm normalized name: iron/folic acid/C/B12/biotin 75 mg iron (5 mg-70 mg)-1 mg-175 mg-120 mcg-300 mcg ORAL CAPSULE, EXTENDED RELEASE MULTIPHASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (5 mg) and Galacto-Oligosaccharides (7.5 g)
Trial: 31671757
Drug: Iron (5
RxNorm normalized name: iron/folic acid/C/B12/biotin 75 mg iron (5 mg-70 mg)-1 mg-175 mg-120 mcg-300 mcg ORAL CAPSULE, EXTENDED RELEASE MULTIPHASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (5 mg)
Trial: 26017328
Drug: Diflunisal 500
RxNorm normalized name: diflunisal 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 500 mg/day
Trial: 24558835
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (as basic treatment)
Trial: 21350839
Drug: rAd2p53 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rAd2p53 gene therapy + RT (n = 22)
Trial: 17419956
Drug: Pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaptanib sodium (intra-ocular injection) for 54 weeks, followed by re-randomization to continue or discontinue treatment.
Trial: 15983290
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10 mg/d)
Trial: 15983290
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 to 40 mg/d)
Trial: 9489629
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with recombinant alpha interferon (IFN-alpha)
Trial: 9489629
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of chemotherapy courses prior to autologous PBSC transplantation
Trial: 11171785
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy
Trial: 2506608
Drug: Alprazolam (AL;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (AL; 0.25 mg)
Trial: 2506608
Drug: Lorazepam (LO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (LO; 1 mg)
Trial: 1176972
Drug: Drug alleged
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug alleged to induce flashbacks (specific drug not mentioned)
Trial: 30732940
Drug: Ritonavir-boosted lopinavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted lopinavir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily)
Trial: 16460251
Drug: 0.2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% CHX spray
Trial: 16460251
Drug: 0.03% TRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% TRN spray
Trial: 16460251
Drug: 0.05% CPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% CPC spray
Trial: 16460251
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (negative control)
Trial: 15166643
Drug: alanine infusion
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alanine infusion (control)
Trial: 11813896
Drug: Azithromycin at
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin at a dose of 10 mg/kg once daily for 3 days, repeated weekly for up to 12 weeks
Trial: 11813896
Drug: Azithromycin at
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin at a dose of 10 mg/kg once daily for 3 days for the first week, repeated for 1 day a week for the following 11 weeks
Trial: 11813896
Drug: Pseudoephedrine hydrochloride
RxNorm normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine hydrochloride (PHCl), 4 mg/kg, 3 times daily for up to 12 weeks
Trial: 3140572
Drug: GnRH-agonist (buserelin)
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-agonist (buserelin) 400 micrograms intranasally once daily
Trial: 29325436
Drug: Schema Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema Therapy
Trial: 21247517
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 or 7.5 mg/day
Trial: 12610188
Drug: paclitaxel, estramustine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel, estramustine, and oral etoposide (TEE)
Trial: 8721467
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg hyperbaric lignocaine 5%
Trial: 8721467
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hyperbaric lignocaine 5%
Trial: 29019899
Drug: gynecological laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gynecological laparoscopic surgery with mannitol treatment (Group B)
Trial: 25822010
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 3 months (teaching coping skills)
Trial: 25822010
Drug: Supportive nondirective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive nondirective therapy (supportive listening)
Trial: 25822010
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) after excluding subjects on >20 mg/d prednisone equivalent (n = 34)
Trial: 21059778
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg intravenous every six hours until hemodynamic stability, followed by tapering over eight days)
Trial: 17701167
Drug: Control (multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (multivitamin tablet Vitamineral)
Trial: 9527202
Drug: Reduced prime
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced prime (RP) volume (600 to 800 mL)
Trial: 9527202
Drug: Full prime
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full prime (FP) volume (1,400 mL of Plasmalyte solution)
Trial: 2908258
Drug: Fansimef (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansimef (1 tablet containing 250 mg mefloquine + 500 mg sulfadoxine + 25 mg pyrimethamine per week)
Trial: 23816039
Drug: Phytosterol tablets
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol tablets 900 mg twice daily
Trial: 23816039
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice (RYR) 1800 mg twice daily
Trial: 21430512
Drug: Tendon gliding
RxNorm normalized name: Bos taurus tendon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tendon gliding exercises with conventional treatments
Trial: 21430512
Drug: Nerve gliding
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve gliding exercises with conventional treatments
Trial: 21430512
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments (splint and paraffin therapy)
Trial: 20142790
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone tablets (80 or 120 mg/d)
Trial: 20142790
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone treatment